Create New Share
Please enter the email address below of the person you would like to share this article with.
An email will be sent to the recipient with a link to this chosen article.
A source for healthcare professionals to access the latest data and information on the diagnosis, treatment and management of patients with gut related disorders
Dr Fermín Mearin-Manrique
Director of the Department of Gastroenterology, Institute of Functional and Motor Digestive Disorders, Barcelona, Spain
Symptoms in this patient point towards a diagnosis of irritable bowel syndrome (IBS)
IBS is characterised by the presence of recurring abdominal pain linked to changes in the pattern of bowel movements, be it constipation, diarrhoea, or both.1 In accordance with the Rome IV criteria there must be pain at least one day a week, associated with two or more of the following characteristics: defecation, change in frequency of bowel movements, change in stool consistency. Additionally, the criteria must have been met for at least the past three months, and the symptoms must have begun at least six months prior to the diagnosis.1
IBS commonly overlaps with other functional bowel disorders, such as functional constipation or diarrhoea.1 In fact, in the case that the patient presents with very mild, occasional pain, which only occurs during episodes of diarrhoea their symptoms would meet more of the criteria for functional diarrhoea than for IBS. Therefore, before ruling out any possible organic causes of diarrhoea or pathophysiological mechanisms, the initial diagnosis should be diarrhoea and not IBS.1
Job number: JB57410GBj Date of Preparation: June 2019
You must be registered to GutNews.org
to view or download these files
Brief report: length of ileal resection correlates with severity of bile acid malabsorption in Crohn’s disease
In patients with Crohn’s disease who had a prior surgical resection there was a modest correlation between the length of ileal resection and the severity of bile acid malabsorption (BAM), as defined by tauroselcholic (75selenium) acid (SeHCAT) retention values. Response to bile salt sequestrant therapy was not dependent on SeHCAT retention values.
Are you a healthcare professional?
This educational website is developed by GE Healthcare for educational purposes. The information contained within this website is intended for healthcare professionals. By entering this website you are confirming that you are a healthcare professional.
This link opens another website that is not under the review or control of GE Healthcare Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it.